GI Dysmotility Symptoms Are Not Associated With Increased L-Dopa Requirements in Parkinson's Disease Patients

被引：0
|
作者：
Chang, Jocelyn [1 ]
Gadi, Sanjay [2 ]
Kuo, Braden [3 ]
Pasricha, Trisha S. [3 ]
机构：
[1] Tufts Univ, Sch Med, Boston, MA 02111 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2022年 / 117卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1548
引用
收藏
页码：S1107 / S1108
页数：2
相关论文
共 50 条
  • [31] THE L-DOPA RESPONSE IN PATHOLOGICALLY CONFIRMED PARKINSON'S DISEASE
    Pitz, Vanessa
    Malek, Naveed
    Grosset, Katherine A.
    Grosset, Donald G.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (10):
  • [32] L-DOPA and cortical associative plasticity in Parkinson's disease
    Suppa, Antonio
    Bologna, Matteo
    Berardelli, Alfredo
    CLINICAL NEUROPHYSIOLOGY, 2013, 124 (04) : 638 - 639
  • [33] Paradoxical response to L-dopa and apomorphine in the Parkinson's disease
    García-Soldevilla, MA
    Puertas, I
    Barcenilla, B
    Sayed, Y
    García-Albea, E
    Jiménez-Jiménez, FJ
    MOVEMENT DISORDERS, 2002, 17 : S96 - S96
  • [34] Parkinson's disease, L-DOPA, and endogenous morphine: A revisit
    Stefano, George B.
    Mantione, Kirk J.
    Kralickova, Milena
    Ptacek, Radek
    Kuzelova, Hana
    Esch, Tobias
    Kream, Richard M.
    MEDICAL SCIENCE MONITOR, 2012, 18 (08): : RA133 - RA137
  • [35] L-DOPA for Parkinson's disease-a bittersweet pill
    Lane, Emma L.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (03) : 384 - 398
  • [36] L-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski, Janusz
    Nistico, Robert
    Berretta, Nicola
    Guatteo, Ezia
    Bernardi, Giorgio
    Mercuri, Nicola B.
    PROGRESS IN NEUROBIOLOGY, 2011, 94 (04) : 389 - 407
  • [37] L-dopa impairs associative learning in Parkinson's disease
    Shohamy, D
    Myers, CE
    Onlaor, S
    Gluck, MA
    JOURNAL OF COGNITIVE NEUROSCIENCE, 2002, : 84 - 84
  • [38] Parkinson's disease: Progression and mortality in the L-DOPA era
    DiRocco, A
    Molinari, SP
    Kollmeier, B
    Yahr, MD
    PARKINSON'S DISEASE, 1996, 69 : 3 - 11
  • [39] Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease
    Blandini, F
    Fancellu, R
    Martignoni, E
    Mangiagalli, A
    Pacchetti, C
    Samuele, A
    Nappi, G
    CLINICAL CHEMISTRY, 2001, 47 (06) : 1102 - 1104
  • [40] Parkinson's Disease and Melanoma: Is There an Increased Incidence of their Joint Occurrence under L-Dopa Therapy?
    Michelmann, S.
    Moll, I.
    Koch, M. O.
    Hauswirth, U.
    AKTUELLE NEUROLOGIE, 2013, 40 (06) : 309 - 314
12345